Non-Small Cell Lung Carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
Disease Exacerbation
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma.
|
29754146 |
2018 |
Hydrocephalus
|
0.200 |
Biomarker
|
disease |
MGD |
A specific, nonproliferative role for E2F-5 in choroid plexus function revealed by gene targeting.
|
9553039 |
1998 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, rescue assay revealed E2F5 to be essential for the tumor suppressive effects of miR-32.
|
31173286 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Co-localization of E2F5 with pSMAD3L in the nuclei of tumor and PC3 cells indicated a functional interface between the proteins.
|
26919443 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast, distinct MIN-tumor-associated DNA amplifications were detected for E2F5 (8p22-q21.3), GARP (11q13.5-q14), ATM (11q22.3), KAL (Xp22.3), and XIST (Xq13.2) as well as DNA deletions for RAF1 (3p25), DCC (18q21.3), and KEN (21q tel). aCGH revealed distinct DNA copy number changes of oncogenes and tumor suppressor genes in CIN- and MIN-type sporadic colorectal carcinomas.
|
17143621 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activation of Drp1 with E2F5-mimetic peptide for inducing Drp1 mitochondrial localization enhanced ceramide-mediated mitophagy and led to tumor suppression in HPV-negative HNSCC-derived xenograft tumors in response to cisplatin in SCID mice.
|
28606997 |
2017 |
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.
|
23377984 |
2013 |
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
miR-154-5p may play an important role as an inhibitor of proliferation, migration and invasion of PCa by targeting E2F5 in PCa cell lines.
|
27074041 |
2017 |
Malignant neoplasm of prostate
|
0.050 |
Biomarker
|
disease |
BEFREE |
Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
|
26919443 |
2016 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Function of E2F5 and p38 in prostate cancer was investigated using siRNA-treatment of PC3 cell-line followed by analyses of associated components and cell cycle.
|
26919443 |
2016 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
miR-154-5p may play an important role as an inhibitor of proliferation, migration and invasion of PCa by targeting E2F5 in PCa cell lines.
|
27074041 |
2017 |
Prostate carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Analysis of genetic aberrations on chromosomal region 8q21-24 identifies E2F5 as an oncogene with copy number gain in prostate cancer.
|
23377984 |
2013 |
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Reintroduction of E2F5 without 3'-untranslated region reversed the inhibitory effects of miR-613 on cell proliferation and invasion.
|
28351331 |
2017 |
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Overexpression of miR-106b shortened the G0/G1 phase and accelerated cell cycle progression, while reducing p21 and E2F5, without any significant effects on the capacity for migration and invasion of gastric cancer cells.
|
23803041 |
2013 |
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Reintroduction of FMNL2 or E2F5 without 3'UTR region reversed the inhibitory effects of miR-34a on cell proliferation and invasion.
|
26103003 |
2015 |
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The effects of forced miR-154-5p expression or E2F transcription factor 5 (E2F5) knockdown on PCa cells were evaluated by cell proliferation, flow cytometry, cell migration and invasion assays as well as by Western blot analysis.
|
27074041 |
2017 |
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, we identified a positive correlation between SNHG16 and E2F5 in breast cancer tissues.
|
28232182 |
2017 |
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
This E2F-5-positive breast cancer subtype was associated with an ER(-)/PgR(-)/HER2(-) status, a basal phenotype, and a worse clinical outcome.
|
19259095 |
2009 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Taken together, these results demonstrated that SNHG6 plays a crucial role in CRC progression via miR-181a-5p/E2F5 axis.
|
30666158 |
2019 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Our study suggests that miR-34a is an important tumor suppressor of CRC progression by targeting FMNL2 and E2F5, thus providing new insight into the molecular mechanisms underlying CRC progression and establishing a strong potential for the application of miR-34a as a novel therapeutic marker against CRC.
|
26103003 |
2015 |
Colorectal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In contrast, distinct MIN-tumor-associated DNA amplifications were detected for E2F5 (8p22-q21.3), GARP (11q13.5-q14), ATM (11q22.3), KAL (Xp22.3), and XIST (Xq13.2) as well as DNA deletions for RAF1 (3p25), DCC (18q21.3), and KEN (21q tel). aCGH revealed distinct DNA copy number changes of oncogenes and tumor suppressor genes in CIN- and MIN-type sporadic colorectal carcinomas.
|
17143621 |
2007 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In addition, we identified a positive correlation between SNHG16 and E2F5 in breast cancer tissues.
|
28232182 |
2017 |
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
This E2F-5-positive breast cancer subtype was associated with an ER(-)/PgR(-)/HER2(-) status, a basal phenotype, and a worse clinical outcome.
|
19259095 |
2009 |
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Our study provides a new insight in the crucial role of E2F cross-talk, especially the role of the inhibiting transcription factors E2F4 and E2F5, in the tumor biology of cancer and its possible usefulness as targets in anti-cancer therapy.
|
16721044 |
2006 |